Affiliation: Stanford University
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationL Johnston
Department of Medicine, Stanford University, Stanford, CA, USA
Bone Marrow Transplant 47:581-8. 2012..The severe toxicities in the patients receiving the BU-containing preparative regimens limited the continued use of sirolimus and MMF for the prevention of AGVHD...
- Autologous hematopoietic cell transplantation in non-Hodgkin's lymphomaL J Johnston
Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA
Hematol Oncol Clin North Am 13:889-918. 1999..A large number of NHL patients succumb to their disease, so it is hoped that alternate therapies, such as cytokines, monoclonal antibodies, and vaccines, may improve the results of HDT...
- Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphomaL J Johnston
Division of Bone Marrow Transplantation, Stanford University, California 94305, USA
Biol Blood Marrow Transplant 6:555-62. 2000..We conclude that HDSC/AHCT in refractory/recurrent NHL is associated with considerable acute and chronic toxicities. Given the toxicity profile, efficacy data were not sufficiently promising to warrant further study...
- Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensityLaura Johnston
Division of Blood and Marrow Transplantation, Stanford University, 300 Pasteur Drive, H3249, Stanford, CA 94305, USA
Best Pract Res Clin Haematol 21:177-92. 2008..More formal comparisons of the different graft sources as well as preparative regimen intensities will be required to determine a more accurate picture of the differences between these transplantation alternatives...
- Rapamycin (sirolimus) for treatment of chronic graft-versus-host diseaseLaura J Johnston
Stanford University, Stanford, California 94305, USA
Biol Blood Marrow Transplant 11:47-55. 2005..Given the significant toxicities described, investigation of altered administration of rapamycin and calcineurin inhibitors should be pursued in future cGVHD trials...
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaSally Arai
Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
Biol Blood Marrow Transplant 16:1145-54. 2010..This new transplant regimen for HL resulted in decreased BCNU toxicity with encouraging FFP and OS. A prospective, risk-modeled comparison of this new combination with other conditioning regimens is warranted...
- Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasmsJonathan Benjamin
Division of Blood and Marrow Transplantation, Stanford University, Stanford, California
Biol Blood Marrow Transplant 20:837-43. 2014..The safety and tolerability of TLI-ATG, as exemplified by its low NRM, provides a foundation for further risk-adapted or prophylactic interventions to prevent disease progression...
- Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimenJoanna M Schaenman
Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305 5623, USA
Biol Blood Marrow Transplant 17:693-702. 2011..These observations demonstrate the dynamic nature of immunity in relation to CMV antigen exposure in the complex environment resulting from NMA conditions where both donor and residual recipient immune response affect viral control...
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphomaLisa Y Law
Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
Biol Blood Marrow Transplant 12:703-11. 2006..Patients who had required >3 previous chemotherapy regimens before HCT had an increased probability of relapse. CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT...
- Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell doseThai M Cao
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Schol of Medicine, 300 Pasteur Dr, H3249, MC 5623, Stanford, CA 94305 5623, USA
Blood 105:2300-6. 2005..003; RR = 0.2, 95% CI = 0.1-0.6) was associated with improved freedom from progression. Infusion of low G-PBMC CD8+ T-cell dose for reduced-intensity allografting may adversely affect T-cell engraftment and survival outcome...
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donorsHolbrook E Kohrt
Department of Medicine, Stanford University School of Medicine, CA 94305, USA
Blood 114:1099-109. 2009..Active trial registration currently at clinicaltrials.gov under IDs of NCT00185640 and NCT00186615...
- Protective conditioning for acute graft-versus-host diseaseRobert Lowsky
Department of Medicine, Stanford University School of Medicine, Stanford, Calif, USA
N Engl J Med 353:1321-31. 2005..Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans...
- CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignanciesThai M Cao
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5623, USA
Exp Hematol 33:279-85. 2005..G-PBMC cell contents were analyzed for influence on outcomes...
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphomaSteven M Horwitz
Division of Oncology, Stanford University Medical Center, Ste 202, 1000 Welch Rd, Palo Alto, CA 94304, USA
Blood 103:777-83. 2004..Rituximab after HDT and HCT is feasible, and these phase 2 data support the current US Intergroup phase 3 trial in recurrent/refractory diffuse large cell lymphoma...
- Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialMary E D Flowers
Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA 98109, USA
Blood 100:415-9. 2002..Assessment of the overall benefits of PBSCT compared to BMT will require continued long-term follow up of morbidity associated with chronic GVHD...